Bristol Myers (BMY) Squibb announced the presentation of new clinical trial and real-world data for Camzyos at the American College of Cardiology’s, ACC, Annual Scientific Session & Expo, taking place March 28-30, 2026, in New Orleans, Louisiana. Presentations at ACC will build upon the comprehensive and mature evidence base in symptomatic obstructive hypertrophic cardiomyopathy. New data include multiple real-world data analyses demonstrating the consistent effectiveness and safety profile of Camzyos in adults, as well as full results from SCOUT-HCM, the first Phase 3 clinical trial evaluating a cardiac myosin inhibitor as a potential treatment for adolescents with oHCM.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers announces expanded approvals for Opdivo in U.S., EU,
- Trump Trade: President issues short-term waiver of Jones Act
- Trump claims TrumpRx website offers lowest prices, review says not so, NYT says
- Bristol-Myers Squibb Advances BMS-986278 Through Key Heart Safety Study
- Bristol Myers price target raised to $60 from $53 at HSBC